SN-38 glucuronide-d₃

Cat. No.: HY-W653919: FAQs
Data Sheet Handling Instructions

Molarity Calculator

SN-38 glucuronide-d₃ is deuterium labeled SN-38 glucuronide. SN-38 glucuronide is an inactive metabolite of the anticancer active molecule Irinotecan (HY-16562) and has toxic effects on the gastrointestinal tract. Irinotecan is a topoisomerase I inhibitor which can be used for researching colon and rectal cancer.

For research use only. We do not sell to patients.

SN-38 glucuronide-d<sub>3</sub> Chemical Structure

SN-38 glucuronide-d₃ Chemical Structure

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of SN-38 glucuronide-d₃:

SN-38 glucuronide Get quote

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description	SN-38 glucuronide-d₃ is deuterium labeled SN-38 glucuronide. SN-38 glucuronide is an inactive metabolite of the anticancer active molecule Irinotecan (HY-16562) and has toxic effects on the gastrointestinal tract. Irinotecan is a topoisomerase I inhibitor which can be used for researching colon and rectal cancer^[1]^[2]^[3]^[4].
Molecular Weight	571.55
Formula	C₂₈H₂₅D₃N₂O₁₁
Unlabeled CAS	121080-63-5
SMILES	O=C1C2=C(C=C3C4=NC5=CC=C(C=C5C(CC([2H])([2H])[2H])=C4CN31)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(O)=O)O)O)O)[C@@](CC)(C(OC2)=O)O
Shipping	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation	Data Sheet (273 KB) Handling Instructions (2659 KB)
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief] [2]. Atasilp C, et al. Determination of irinotecan, SN-38 and SN-38 glucuronide using HPLC/MS/MS: Application in a clinical pharmacokinetic and personalized medicine in colorectal cancer patients. J Clin Lab Anal. 2018 Jan;32(1):e22217. [Content Brief] [3]. Pellock SJ, et al. Three structurally and functionally distinct β-glucuronidases from the human gut microbe Bacteroides uniformis. J Biol Chem. 2018;293(48):18559-18573. [Content Brief] [4]. Wallace BD, et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science. 2010 Nov 5;330(6005):831-5. [Content Brief] [5]. Ohtsuka K, et al. Intracellular conversion of irinotecan to its active form, SN-38, by native carboxylesterase in human non-small cell lung cancer[J]. Lung Cancer, 2003, 41(2): 187-198.